death from semaglutide Ozempic cuts risk of kidney disease, major study finds GLP-1 use linked to better
Description
Mol Metab 18:314
Off-label use in younger patients occurs in clinical practice, but such decisions require careful provider assessment of risk-benefit, family history, and metabolic status
Highlight: Maximus focus on overall health makes it a good choice for those looking to combine weight loss with general wellness
10.3389/fphar.2023.975830 Front
Comparative profiling against single and dual incretin receptor compounds in preclinical models
